Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary… Read more
Recce Pharmaceuticals Ltd (RECEF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 4.429x
Based on the latest financial reports, Recce Pharmaceuticals Ltd (RECEF) has a cash flow conversion efficiency ratio of 4.429x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.52 Million) by net assets ($-3.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Recce Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Recce Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Recce Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Recce Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kuang Hong Arts Management
TWO:6596
|
-0.016x |
|
GOLFZON Co. Ltd
KQ:215000
|
0.052x |
|
Empresas Lipigas S.A.
SN:LIPIGAS
|
0.261x |
|
Tigo Energy Inc.
NASDAQ:TYGO
|
0.119x |
|
APAC Resources Limited
F:FZV1
|
-0.013x |
|
Globaltek Fabrication Co Ltd
TW:4566
|
0.004x |
|
Foraco International SA
PINK:FRACF
|
0.067x |
|
Desiccant Technology Corporation
TW:5292
|
0.101x |
Annual Cash Flow Conversion Efficiency for Recce Pharmaceuticals Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Recce Pharmaceuticals Ltd from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-3.05 Million | $-20.44 Million | 6.698x | +390.36% |
| 2024-06-30 | $-9.52 Million | $-13.01 Million | 1.366x | -72.13% |
| 2023-06-30 | $-2.59 Million | $-12.69 Million | 4.901x | +647.26% |
| 2022-06-30 | $10.06 Million | $-9.01 Million | -0.896x | -133.73% |
| 2021-06-30 | $20.50 Million | $-7.86 Million | -0.383x | +76.73% |
| 2020-06-30 | $2.31 Million | $-3.81 Million | -1.646x | -125.56% |
| 2019-06-30 | $-405.60K | $-2.61 Million | 6.440x | +358.34% |
| 2018-06-30 | $694.91K | $-1.73 Million | -2.493x | +41.10% |
| 2017-06-30 | $590.14K | $-2.50 Million | -4.233x | -825.16% |
| 2016-06-30 | $3.51 Million | $-1.61 Million | -0.458x | -628.29% |
| 2015-06-30 | $4.71 Million | $-296.14K | -0.063x | +69.36% |
| 2014-06-30 | $-55.74K | $11.43K | -0.205x | -- |